ArticleTurkish journal of pharmaceutical sciences2025
Development and Validation of High-Performance Thin Layer Chromatographic Method for the Simultaneous Estimation of Dapagliflozin and Vildagliptin in Fixed-Dose Combination.
Article in Turkish journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The objective of this study was to develop a simple, precise, and accurate high-performance thin-layer chromatographic (HPTLC) method for the simultaneous estimation of dapagliflozin (DAP) and vildagliptin (VIL) in a combined pharmaceutical formulation. Managing diabetes often involves using a combination of drugs to better control blood sugar levels. One such effective formulation is combination of DAP, an SGLT2 inhibitor, with VIL, a DPP-4 inhibitor, in a single formulation. To ensure the quality and consistency of these combination products, it is important to have a simple and reliable method for analyzing both drugs simultaneously. Materials and Methods: An aluminium-backed pre-coated silica gel 60 F Results: The developed method successfully separated the analytes with retardation factor values of 0.57±0.02 for DAP and 0.26±0.02 for VIL. The method exhibited linearity in the concentration ranges of 0.6 to 1.4 μg per band for DAP, with a correlation coefficient (r²) of 0.997 and 6 to 14 μg per band for VIL, with an r² of 0.998. The limit of detection was found to be 0.02 μg/band for DAP and 0.19 μg/band for VIL. Similarly, the limit of quantification was determined to be 0.07 μg/band for DAP and 0.58 μg/band for VIL. Conclusion: The proposed HPTLC method allows for the simultaneous estimation of DAP and VIL with high accuracy, precision, and sensitivity. Owing to its satisfactory analytical performance, the method is suitable for routine quality control of combined dosage forms containing DAP and VIL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.